{"meta":{"query_hash":"9e54509d9daa","filters":{"venue":"International Journal of Pharmaceutical and Biological Science Archive"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/9e54509d9daa","api":"https://metacan.xera.ac/api/v1/cohort?venue=International+Journal+of+Pharmaceutical+and+Biological+Science+Archive"},"results":[{"id":"W3175943885","doi":"","title":"COMPARISON OF NEW DRUG APPROV AL PROCEDURES AND REGULATORY STRUCTURES IN TURKEY AND CANADA","year":2013,"lang":"en","type":"article","venue":"International Journal of Pharmaceutical and Biological Science Archive","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Marketing authorization; Authorization; Business; Regulatory affairs; Drug; Clinical trial; Process (computing); Drug development; Drug approval; New drug application; Marketing; Innovator; Regulatory science; Public relations; Medicine; Pharmacology; Political science; Public administration; Finance; Computer security; Computer science","score_opus":0.28281380338523104,"score_gpt":0.5394769818318773,"score_spread":0.25666317844664627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175943885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58165723,0.03038542,0.0038297204,0.014352902,0.0005995423,0.0010099177,0.009512518,0.00045591983,0.35819677],"genre_scores_gemma":[0.94489825,0.008870081,0.0030135508,0.002381297,0.000067216555,0.0001478514,0.0029270768,0.00013578105,0.037558947],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9896774,0.0008045356,0.0006603863,0.00073381787,0.0053880224,0.002735817],"domain_scores_gemma":[0.9796897,0.0026407733,0.0020264387,0.000417422,0.012937292,0.002288325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004157677,0.00029491834,0.0003600305,0.005266315,0.0031531863,0.005008839,0.0013527779,0.0010056588,0.007738771],"category_scores_gemma":[0.012105391,0.00043238598,0.0009363542,0.0056811585,0.0016857906,0.00093556894,0.0010848214,0.0014109443,0.00074662035],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032698452,0.00055620476,0.2639041,0.0024077995,0.00046612308,0.0033148474,0.006716959,0.007969395,0.0049027517,0.27423424,0.097535275,0.3347225],"study_design_scores_gemma":[0.0002473778,0.0003557138,0.6937999,0.0009376517,0.00038656802,0.0013314973,0.0072870958,0.0039092023,0.003762058,0.0020841663,0.28560916,0.0002895948],"about_ca_topic_score_codex":0.9465078,"about_ca_topic_score_gemma":0.96649617,"teacher_disagreement_score":0.9247954,"about_ca_system_score_codex":0.0752046,"about_ca_system_score_gemma":0.11538087,"threshold_uncertainty_score":0.5456501},"labels":[],"label_agreement":null}]}